期刊簡(jiǎn)介預(yù)計(jì)審稿時(shí)間： 一般,3-8周 約8周

Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.

These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.

Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.

《核醫(yī)學(xué)與生物學(xué)》發(fā)表涉及放射性藥物科學(xué)各個(gè)方面的原創(chuàng)研究：合成、體外和離體研究、通過(guò)解剖或成像進(jìn)行的體內(nèi)生物分布、放射性藥理學(xué)、放射性藥理學(xué)以及新型靶向放射性示蹤劑的轉(zhuǎn)化臨床研究。靶標(biāo)對(duì)未滿足的臨床需求的重要性應(yīng)是首要考慮因素。如果提交的新型放射性藥物合成沒(méi)有體外或體內(nèi)數(shù)據(jù)，則必須強(qiáng)調(diào)化學(xué)的獨(dú)特性。

這些多學(xué)科研究應(yīng)驗(yàn)證定位機(jī)制，無(wú)論探針是基于與受體、酶、腫瘤抗原還是另一個(gè)明確定義的靶標(biāo)的結(jié)合。研究應(yīng)旨在評(píng)估化學(xué)和放射性藥物特性如何影響藥代動(dòng)力學(xué)、藥效學(xué)或治療效果。理想情況下，研究將解決探針對(duì)疾病或治療變化的敏感性，盡管僅驗(yàn)證機(jī)制的研究也是可以接受的。放射性藥物學(xué)實(shí)踐涉及制備、自動(dòng)化、質(zhì)量控制、分配以及適用于放射性藥物對(duì)人體的鑒定和管理的法規(guī)等問(wèn)題，是發(fā)展過(guò)程的一個(gè)重要方面，但前提是該研究對(duì)該領(lǐng)域有重大影響。

只要標(biāo)記化合物定位和治療效果的特異性得到解決，那么關(guān)于治療性放射性藥物主題的貢獻(xiàn)也是合適的。

《Nuclear Medicine And Biology》(核醫(yī)學(xué)與生物學(xué))編輯部通訊方式為ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710。如果您需要協(xié)助投稿或潤(rùn)稿服務(wù)，您可以咨詢我們的客服老師。我們專注于期刊咨詢服務(wù)十年，熟悉發(fā)表政策，可為您提供一對(duì)一投稿指導(dǎo)，避免您在投稿時(shí)頻繁碰壁，節(jié)省您的寶貴時(shí)間，有效提升發(fā)表機(jī)率，確保SCI檢索（檢索不了全額退款）。我們視信譽(yù)為生命，多方面確保文章安全保密，在任何情況下都不會(huì)泄露您的個(gè)人信息或稿件內(nèi)容。